Currently in the preclinical phase, Yomi Pharma is developing a personalized therapy targeting treatment-resistant non-small cell lung cancer, the most common and aggressive form of lung cancer. Our lead asset is a therapeutic peptide that uniquely inhibits the EGFR signaling pathway, remaining effective even after resistance-driving secondary mutations, offering hope to a large number of patients who have failed treatment.